Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms
IHC-detected MDM2 overexpression identifies a distinct subset of plasma cell neoplasms characterized by reduced early treatment responsiveness and significantly shorter RFS. These findings support the potential of MDM2 as a prognostic biomarker for early relapse risk in MM. Incorporating MDM2 assessment into diagnostic and prognostic workflows may enable more individualized treatment approaches. Further validation through prospective studies is recommended.
Authors
- Mahitab Ibrahim Eltohamy (ORCID: https://orcid.org/0000-0003-4974-242X)
- Amira Darwish (ORCID: https://orcid.org/0000-0001-6370-0272)
- Noura A A Ebrahim
- Habiba Elfandy (ORCID: https://orcid.org/0000-0003-0021-8731)
- Aya Mohamed Adel Arafat
Institutions
- Cairo University (EG)
- National Water Research Center (EG)
- Children Cancer Hospital (EG)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.5306/wjco.v17.i1.111426
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00